Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents

被引:21
作者
Glick, ID
Lemmens, P
Vester-Blokland, E
机构
[1] NV Organon, NL-5340 BH Oss, Netherlands
[2] Janssen Res Fdn, B-2340 Beerse, Belgium
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
risperidone; haloperidol; schizophrenia; efficacy; PANSS; double-blind studies;
D O I
10.1097/00004850-200109000-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Combined data on efficacy were available from 12 double-blind short-term (maximum 8 weeks) trials comparing risperidone and other antipsychotics in patients with chronic schizophrenia. Patients received risperidone (n = 1056) or other antipsychotics (n = 703). Haloperidol (n = 473) was the most frequently prescribed other antipsychotic. Efficacy assessments include the Positive and Negative Syndrome Scale (PANSS) total, subscale (positive symptoms, negative symptoms and general psychopathology), cluster (cognitive and affective symptoms) and item (anxiety and hostility) scores. At endpoint, the mean decrease from baseline in PANSS total scores was significantly greater for patients receiving risperidone (-20.9) than other antipsychotics (-16.2; P < 0.001), or the subset receiving haloperidol (-14.3; P < 0.001). Risperidone-treated patients showed a significantly greater decrease in the positive (P < 0.01), negative (P < 0.05) and general psychopathology (P < 0.001) scores than patients receiving other antipsychotics or haloperidol. Scores for cognition, affective symptoms, anxiety and hostility each improved significantly (P < 0.05) more for patients receiving risperidone than those receiving other antipsychotics or haloperidol. Efficacy data on patients with an acute exacerbation were available from seven trials (risperidone n = 372, other antipsychotics n = 285, including haloperidol n = 120). At endpoint, the mean decrease from baseline in PANSS total scores was significantly greater for patients receiving risperidone (-24.7) than other antipsychotics (-19.8, P < 0.01) including haloperidol (-19.8, P < 0.05). Risperidone-treated patients also showed a greater decrease in positive symptom scores (-7.8) than those receiving other antipsychotics (-6.3; P < 0.01) or haloperidol (-7.1). A <greater than or equal to> 20% reduction in PANSS total score with risperidone, haloperidol and other antipsychotics was achieved by 65.9%, 54.3% and 54.9%, respectively; a greater than or equal to 30% PANSS reduction by 54.0%, 46.6% and 46.5% of patients, respectively; and a greater than or equal to 40% reduction by 43.8%, 33.7% and 34.4% of patients, respectively. These findings are consistent with earlier findings that show risperidone is more efficacious than haloperidol for reducing the symptoms of schizophrenia. Int Clin Psychopharmacol 16:265-274 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 46 条
[1]  
Abi-Dargham A, 1997, J NEUROPSYCH CLIN N, V9, P1
[2]  
ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789
[3]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[4]  
ARANA GW, 1995, COMPREHENSIVE TXB PS, V2, P1919
[5]  
AZORIN JM, 1995, ACTA PSYCHIAT SCAND, V91, P20
[6]   Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients [J].
Blin, O ;
Azorin, JM ;
Bouhours, P .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (01) :38-44
[7]   Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study [J].
Bondolfi, G ;
Dufour, H ;
Patris, M ;
May, JP ;
Billeter, U ;
Eap, CB ;
Baumann, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :499-504
[8]   SEROTONIN, SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUG-ACTION [J].
BREIER, A .
SCHIZOPHRENIA RESEARCH, 1995, 14 (03) :187-202
[9]   DOMAINS OF PSYCHOPATHOLOGY - AN APPROACH TO THE REDUCTION OF HETEROGENEITY IN SCHIZOPHRENIA [J].
BUCHANAN, RW ;
CARPENTER, WT .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1994, 182 (04) :193-204
[10]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96